Dear Friends and Colleagues,

It is our great pleasure to invite you to the International Symposium on Homologous Recombination and DNA Repair: From Bench to Clinic 2025, taking place on June 26–27, 2025, at the Biomedical Research Foundation of the Academy of Athens.

The meeting will focus on the mechanisms involved in DNA Damage Repair (DDR) and the development of new anticancer therapeutic possibilities. This symposium will bring together academics, molecular and translational biologists as well as clinicians covering a wide range of expertise, including clinical and laboratory medicine, basic science, diagnostics and the private sector. The event will explore fundamental aspects of DNA repair, with a focus on homologous recombination, molecular tools for identifying tumours with DNA repair deficiencies, and the latest clinical advancements in the field. The biology behind DDR and genomic instability constitutes the basis for the effective development of new therapeutic anticancer approaches including immunotherapy and targeted DNA damaging agents.

Key topics include:

  • Basic biology of DNA damage response, with an emphasis on homologous recombination
  • Development of inhibitors leveraging synthetic lethality
  • Current and emerging methodologies for detecting homologous recombination deficiency for patient stratification
  • Clinical applications of DNA repair inhibitors, alone or in combination with other therapies, across various tumour types.

There will be short oral presentations of selected posters as well as an open poster session.
The meeting also offers the opportunity to Biotechnology companies to present their latest technological developments and projects in the exhibition space.

We welcome scientists, clinicians, students, and healthcare professionals interested in DNA repair to join us for this exciting event.

Warm regards,

The Organizing Committee

Pr. Α. Klinakis Biochemical Research Foundation Academy of Athens (BRFAA), GR
Dr. P. Constantoulakis PhD GENOTYPOS MSA, Athens, GR
Pr. W. Niedzwiedz PhD The Institute of Cancer Research, London, UK
Dr. J. Loizou PhD The Institute of Cancer Research, London, UK
Dr. S. Linardopoulos PhD Oncology AstraZeneca, Cambridge, UK

* English is the official language of the meeting

Special thanks for the support

Company presentation

Amoy Diagnostics Co., Ltd. (AmoyDx) is a leading company in the field of precision oncology diagnostics, committed to continuous medical innovation. The company provides high-quality, regulatory-compliant companion diagnostic products and services, enabling patients to benefit from truly personalized cancer care.

AmoyDx holds several prestigious accreditations, including National Enterprise Technology Center, “Little Giant” Enterprise of Specialization and Innovation, Single Champion of Manufacturing, Postdoctoral Research Station, and Demonstration Center for Gene Testing Technologies. Its proprietary technology platforms – ADx-ARMS®, Super-ARMS®, ddCapture®, and ADx-HANDLE® – are protected by patents in China, the United States, Europe, and Japan.

The company has received the Second Prize of the National Science and Technology Progress Award and the China Patent Silver Award, with product lines covering key indications across major tumor types. Several products remain without domestic equivalents and have been approved for marketing in Japan, South Korea, and the European Union, with some included in Japanese and Korean reimbursement systems – marking milestones in the internationalization of China’s cancer diagnostics industry.

Today, AmoyDx’s products and services are used in dozens of countries and regions worldwide, benefiting hundreds of thousands of cancer patients annually. Through partnerships with leading pharmaceutical companies, AmoyDx continues to drive innovation at the source, establishing itself as a globally recognized Chinese brand in the field of companion diagnostics.

  • Albertella M. D Phil, Senior Director, Bioscience, AstraZeneca Oncology R&D, Cambridge, UK
  • Anastasopoulou V. Postdoctoral Researcher, Hellenic Oncology Research Group, Athens, Greece
  • Antonarakis S. Professor Emeritus, University of Geneva Medical School, Switzerland / MediGenome, Swiss
    Institute of Genomic Medicine, Geneva, Switzerland
  • Burghel G. Consultant Clinical Scientist, North West Genomic Laboratory Hub) / Honorary Senior Lecturer,
    University of Manchester, UK
  • Chapman R. MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK
  • Christoforou E. Senior Scientist, AstraZeneca, Early Oncology R&D, Translational Medicine Epigenomics, UK
  • Christopoulou G. MSc, PhD, Lab Director, Head of Genetics & Genomics Dpt, Genotypos S.A.
  • Constantoulakis P. PhD, Scientific Director, Genotypos MSA, Greece
  • Dangaj D. PhD, Privat Docent (Lecturer), Group Leader, Laboratory Tumor Microenvironment and Biomarker
    Discovery, Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, Switzerland
  • Fountzila E. Medical Oncologist, Clinical Associate Professor, European University Cyprus, St Lukes Hospital,
    Thessaloniki, Greece
  • Gagos S. Principal Investigator Biomedical Research Foundation of the Academy of Athens (BRFAA), Greece
  • Garinis G. Professor of Genetics , Department of Biology, University of Crete, Affiliated Group leader at
    IMBB-FORTH, Greece
  • Georgoulias V. Emeritus Professor of Medical Oncology,School of Medicine, University of Crete, Greece
  • Gounaris I. MD, PhD, VP, Head of Clinical Development DNA Damage Response (DDR), Merck KGaA
  • Guerini Rocco E. Associate Professor of Pathology, Department of Oncology and Hemato-Oncology,
    University of Milan, and Chair of Molecular Pathology Unit, Division of Pathology, European Institute of
    Oncology, IRCCS, Milano, Italy
  • Halazonetis Th. Professor, Dept of Molecular and Cellular Biology, University of Geneva, Switzerland
  • Klinakis A. PhD, Investigator – Professor Level, Biochemical Research Foundation Academy of Athens
    (BRFAA), Greece
  • Linardopoulos S. Director, Translational Science, Oncology AstraZeneca, Cambridge, UK
  • Liontos M. Assistant Professor, Departmentof Clinical Therapeutics, National and Kapodistrian University of
    Athens, Greece
  • Loizou J. Group Leader Divisions of Cancer Therapeutics and Breast Cancer Research | Deputy Director
    Centre for Target Validation, The Institute of Cancer Research, UK
  • Malapelle U. Associate Professor in School of Medicine, Chair of Predictive Molecular Pathology Laboratory,
    Department of Public Health of University Federico II of Naples, Naples, Italy
  • Niedzwiedz W. Professor, PhD, Genome Instability and Cancer Team, The Institute of Cancer Research,
    London, UK
  • Papadopoulou Eir. PhD, International Laboratory Director, Genekor Medical S.A., Greece
  • Pasero Ph. Institute of Human Genetics, CNRS and University of Montpellier, France
  • Rampias Th. PhD, Investigator – Assistant Professor Level, Biochemical Research Foundation Academy of
    Athens (BRFAA), Greece
  • Sammut S.J. MD, PhD, Group Leader, Cancer Dynamics Lab, Consultant Medical Oncologist, The Royal
    Marsden Hospital, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research,
    Chester Beatty Laboratories, London, UK
  • Soutoglou E. Professor of Genome Stability, Genome Damage and Stability Centre, Sussex University,
    School of Life Sciences, University of Sussex, Brighton, UK
  • Stewart G. Professor, Department of Cancer and Genomic Sciences, University of Birmingham, UK
  • Tan T. Senior Consultant Medical Oncologist, National Cancer Centre Singapore
  • Zakopoulou R. MD, PhD, Medical Oncologist, Locum Consultant, General Anticancer Hospital “Agioi
    Anargyroi”, Athens, Greece
Register here
Download the Program